Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism

Authors:

Abstract
Although subclinical hyperthyroidism (SCH) has been associated with increased risk of osteoporosis and cardiac arrhythmias, its treatment is still controversial. This study was designed as a prospective, randomized, intervention, control-study with a 1-year follow-up in order to investigate whether normalization of serum TSH in SCH using methimazole has favorable bone and heart clinical effects. Fourteen patients with endogenous SCH (not Graves’ disease) were enrolled, 7 (5 women/2 men; group T) were treated with methimazole (2.5–7.5 mg/day), and 7 (5 women/2 men; group C) were followed without treatment; 10 healthy subjects were also included in the study as controls. Serum free-T3 (FT3), free-T4 (FT4) and TSH, thyroid echography, bone stiffness index (SI), as measured by heel ultrasonometry, and 24-h electrocardiography monitoring were obtained. SCH patients exhibited higher systolic and diastolic blood pressure than control subjects. They also had a significantly higher number of both ventricular premature beats (VPB) (mean±SEM: 681 ±238 vs 6±2 beats/24 h; pp=ns). An insignificant therapy effect was observed as far as APB were concerned (826±660 vs 144±75 beats/24 h; p=ns), however their number increased significantly in the untreated group (463±49 vs 215±46 beats/ 24 h; p<0.05). The SI increased significantly as a result of therapy in group T (64.1 ±4.8 vs 70.0±5.3; p<0.02) and was further reduced in group C at the end of the study (69.1 ±7.3 vs 62.9±7.1; p<0.001 ). No adverse effect was observed in group T. In conclusion, anti-thyroid therapy seems to have favorable bone and heart clinical effects in subjects with endogenous SCH.

This publication has 32 references indexed in Scilit: